Lisa A. Hammond

5.6k total citations · 3 hit papers
56 papers, 4.5k citations indexed

About

Lisa A. Hammond is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lisa A. Hammond has authored 56 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 29 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lisa A. Hammond's work include Cancer therapeutics and mechanisms (15 papers), Cancer Treatment and Pharmacology (15 papers) and HER2/EGFR in Cancer Research (11 papers). Lisa A. Hammond is often cited by papers focused on Cancer therapeutics and mechanisms (15 papers), Cancer Treatment and Pharmacology (15 papers) and HER2/EGFR in Cancer Research (11 papers). Lisa A. Hammond collaborates with scholars based in United States, Ireland and United Kingdom. Lisa A. Hammond's co-authors include Eric K. Rowinsky, Anthony W. Tolcher, Chris H. Takimoto, Daniel D. Von Hoff, Manuel Hidalgo, Gary M. Clark, Daniel D. Karp, P. Santabárbara, Mark S. Huberman and Abraham Chachoua and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Lisa A. Hammond

56 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

2004 893 citations Lisa A. Hammond, Eric K. Rowinsky et al. Journal of Clinical Oncology profile →
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

2001 830 citations Manuel Hidalgo, Lillian L. Siu et al. Journal of Clinical Oncology profile →
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

2002 646 citations Lisa A. Hammond, Eric K. Rowinsky et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Lisa A. Hammond

Since Specialization

Citations

This map shows the geographic impact of Lisa A. Hammond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa A. Hammond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa A. Hammond more than expected).

Fields of papers citing papers by Lisa A. Hammond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa A. Hammond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa A. Hammond. The network helps show where Lisa A. Hammond may publish in the future.

Co-authorship network of co-authors of Lisa A. Hammond

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa A. Hammond. A scholar is included among the top collaborators of Lisa A. Hammond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa A. Hammond. Lisa A. Hammond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Factors affecting the advancement of Black nurses into leadership roles: A scoping review 2023 ·Nursing Outlook ·(unknown), (unknown), (unknown), Lisa A. Hammond, (unknown), (unknown), (unknown), (unknown), (unknown)	4
2	Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project 2018 ·British Journal of Cancer ·Giuseppe Gullo, Naomi Walsh, D. Fennelly, (unknown), Janice M. Walshe, Dimitrios Tryfonopoulos, (unknown), Lisa A. Hammond, (unknown), (unknown), (unknown), Cecily Quinn, Enda McDermott, Denis Evoy, Ruth Prichard, James Geraghty, (unknown), John Crown	8
3	Identification of Genes Involved in Pseudomonas aeruginosa Biofilm-Specific Resistance to Antibiotics 2013 ·PLoS ONE ·Li Zhang, (unknown), Lisa A. Hammond, (unknown), (unknown), A. Colavita, Thien‐Fah Mah	54
4	Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland 2012 ·International Journal of Clinical Pharmacy ·Lisa A. Hammond, (unknown), (unknown), (unknown), Martin Henman, Claire Keane	18
5	Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study 2008 ·Cancer Chemotherapy and Pharmacology ·Jordi Rodón, Mitchell Garrison, Lisa A. Hammond, Johann S. de Bono, Lon Smith, Leonardo Forero, Desirée Hao, Chris H. Takimoto, John M. Lambert, Lini Pandite, (unknown), Hongsheng Xie, Anthony W. Tolcher	25
6	Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer 2006 ·Journal of Clinical Oncology ·Anthony W. Tolcher, Desirée Hao, Johann S. de Bono, A. B. Miller, Amita Patnaik, Lisa A. Hammond, Leslie Smetzer, Jill Hood, James A. Merritt, Eric K. Rowinsky, Chris H. Takimoto, (unknown), S. Gail Eckhardt	34
7	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma 2006 ·Cancer Chemotherapy and Pharmacology ·Monica Mita, Eric K. Rowinsky, Leonardo Forero, (unknown), Elżbieta Izbicka, Geoffrey R. Weiss, Muralidhar Beeram, Alain C. Mita, Johann S. de Bono, Anthony W. Tolcher, Lisa A. Hammond, Paul J. Simmons, (unknown), Chris H. Takimoto, Amita Patnaik	32
8	Positron emission tomography (PET): Expanding the horizons of oncology drug development 2003 ·Investigational New Drugs ·Lisa A. Hammond, Louis Denis, (unknown), Paul Jerabek, Charles R. Thomas, John G. Kuhn	59
9	Pharmacokinetic Evaluation of Gefitinib When Administered with Chemotherapy 2003 ·Clinical Lung Cancer ·Lisa A. Hammond	9
10	A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor. 2003 ·PubMed ·Desirée Hao, Lisa A. Hammond, Sabine Eckhardt, Amita Patnaik, Chris H. Takimoto, Garry Schwartz, Andrew Goetz, Anthony W. Tolcher, (unknown), (unknown), Jon I. Williams, Kenneth J. Holroyd, Eric K. Rowinsky	36
11	A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. 2003 ·PubMed ·Mitchell Garrison, Lisa A. Hammond, Charles E. Geyer, Garry Schwartz, Anthony W. Tolcher, Leslie Smetzer, José A. Figueroa, Murray P. Ducharme, John Coyle, Chris H. Takimoto, Robert L. De Jager, Eric K. Rowinsky	14
12	Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. 2003 ·PubMed ·Shazli N. Malik, Lillian L. Siu, Eric K. Rowinsky, Linda A. deGraffenried, Lisa A. Hammond, Jinee Rizzo, Sarah Bacus, Michael G. Brattain, Jeffrey I. Kreisberg, Manuel Hidalgo	104
13	HER-Targeted Tyrosine-Kinase Inhibitors 2002 ·Oncology ·José Baselga, Lisa A. Hammond	50
14	A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. 2002 ·PubMed ·Amita Patnaik, Eric K. Rowinsky, Miguel A. Villalona, Lisa A. Hammond, Carolyn D. Britten, Lillian L. Siu, Andrew Goetz, (unknown), Susan Burton, Frank H. Valone, S. Gail Eckhardt	112
15	Troxacitabine, an l-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies 2002 ·Journal of Clinical Oncology ·Johann S. de Bono, Joseph Stephenson, Sharyn D. Baker, Manuel Hidalgo, Amita Patnaik, Lisa A. Hammond, Geoffrey R. Weiss, Andrew R. Goetz, Lillian L. Siu, (unknown), Jacques Jolivet, Eric K. Rowinsky	16
16	Exploring the mechanisms of action of FB642 at the cellular level 2001 ·Journal of Cancer Research and Clinical Oncology ·Lisa A. Hammond, Karen Davidson, Richard Lawrence, (unknown), Daniel D. Von Hoff, Steve Weitman, Elżbieta Izbicka	25
17	Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel 2001 ·Journal of Clinical Oncology ·Manuel Hidalgo, Cheryl Aylesworth, Lisa A. Hammond, Carolyn D. Britten, Geoffrey R. Weiss, Joseph Stephenson, Garry Schwartz, Amita Patnaik, Lon Smith, (unknown), (unknown), Elora Gupta, Karen J. Ferrante, (unknown), Daryl Sonnichsen, Jamey Skillings, Eric K. Rowinsky	33
18	DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies 2000 ·Journal of Clinical Oncology ·Eric K. Rowinsky, Thomas R. Johnson, Charles E. Geyer, Lisa A. Hammond, S. Gail Eckhardt, Ronald Drengler, Leslie Smetzer, John Coyle, Jinee Rizzo, Garry Schwartz, Anthony W. Tolcher, Daniel D. Von Hoff, Robert L. De Jager	37
19	Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors 1999 ·Journal of Clinical Oncology ·S. Gail Eckhardt, Jinee Rizzo, Kevin Sweeney, G. Cropp, Sharyn D. Baker, Maura A. Kraynak, John G. Kuhn, Miguel A. Villalona‐Calero, Lisa A. Hammond, Geoffrey R. Weiss, (unknown), Lon Smith, Ronald Drengler, John R. Eckardt, (unknown), Alison L. Hannah, Daniel D. Von Hoff, Eric K. Rowinsky	55
20	Deciding about leg-lengthening. 1993 ·PubMed ·Caroline H. Arnott, Lisa A. Hammond	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact